Skip to main content
European Commission logo print header

Diagnostics device for rapid testing of prostate cancer at Point-of-care

Descrizione del progetto

Esame delle urine per il cancro alla prostata

Con gli europei che vivono più a lungo, il cancro alla prostata è diagnosticato in una percentuale sempre maggiore di uomini anziani. Si tratta di una forma comune di cancro che è anche legata all’età: è diffusa al di sopra dei 65 anni ma poco frequente al di sotto dei 40 anni. Secondo le stime, entro il 2030, quando la percentuale di persone di età superiore ai 65 anni sarà più elevata, il numero di casi di cancro alla prostata quadruplicherà. Per ridurre il tasso di mortalità, la diagnosi precoce è fondamentale. In tale contesto il progetto Nevada, finanziato dall’UE, propone un esame non invasivo basato sulle urine in grado di individuare gli uomini a maggior rischio di cancro alla prostata. Il progetto si propone di semplificare ulteriormente l’esame per trasformarlo in un test decentrato.

Obiettivo

Prostate cancer (PCa) is one of the most common types of cancers. As an age-related disease, it is very infrequent below the age of 40 but very common above 65. Currently in Europe, 1 in 7 men will develop PCa before reaching age of 85. With population growth and ageing, the numbers of PCa diagnoses and PCa deaths are likely to substantially increase. It is estimated that by 2030, with an increase in the proportion of people over 65, the number of PCa cases will quadruple. Most PCa’s are first found through a prostate-specific antigen (PSA) blood test. Under the current standard of care, men with an elevated PSA levels and/or abnormal digital rectal exam (DRE) are considered at high risk for cancer and will be referred to a urologist for a biopsy. But most men selected for biopsy could have avoided this painful procedure, with its associated complications and costs. More accurate non-invasive tests could help PCa-free men safely avoid unnecessary biopsies, while helping to identify men who may be harbouring aggressive PCa, who will benefit from earlier detection. In response to this challenge, we have developed Nevada, a non-invasive urine-based test assay that identify those men at increased risk of PCa who may benefit most from earlier detection. We plan to convert our test into a Point of Care assay, resulting in significant savings for the healthcare systems across Europe, by only referring those patients to the hospitals that are at risk for a clinically significant cancer. Upon completion of the project, Nevada will boost the growth of our company generating additional 85 FTEs, revenues of €309M and a ROI of 7.9 by the fifth year after Phase 2 execution. With the help of the SME instrument, MDxHealth aims to complete clinical validations and assay optimization so that it can be commercialized across European markets first, and global markets later on, improving the quality of care of healthcare systems worldwide as well as the PCa patient´s quality of life.

Invito a presentare proposte

H2020-EIC-SMEInst-2018-2020

Vedi altri progetti per questo bando

Bando secondario

H2020-SMEInst-2018-2020-1

Meccanismo di finanziamento

SME-1 - SME instrument phase 1

Coordinatore

MDXHEALTH
Contribution nette de l'UE
€ 50 000,00
Indirizzo
RUE D'ABHOOZ 31
4040 HERSTAL
Belgio

Mostra sulla mappa

PMI

L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.

Regione
Région wallonne Prov. Liège Arr. Liège
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 71 429,00